Another study showed that cfDNA presence at 6 weeks correlated with short PFS and OS in a phase 1/2 study of osimertinib plus bevacizumab as first-line therapy for advanced EGFR-mutant NSCLC using the QX200 BioRad PCR system (28). Here, EGFR is linked to non-small cell lung carcinoma.